Whalesbook
FY26 Financial Performance
Piramal Pharma Ltd. has reported its audited financial results for the fiscal year ending March 31, 2026. The company posted consolidated revenue of ₹8,869 crore, a 3% decrease from the previous year. Full-year EBITDA fell by 28% to ₹1,135 crore. A net loss of ₹326 crore was recorded for FY26, significantly impacted by an exceptional ₹176 crore charge for asset impairment.
Fourth Quarter Results
In the fourth quarter of FY26, Piramal Pharma's revenue remained flat year-on-year at ₹2,752 crore. However, EBITDA for the quarter declined 16% to ₹507 crore. These results reflect ongoing challenges faced by the company during the fiscal year.
Company Outlook: Eyes on FY27 Growth
Piramal Pharma described FY26 as a "challenging transitional year," citing factors like inventory destocking and slower order inflows. Despite this, the company expressed optimism for fiscal year 2027 (FY27), anticipating a return to growth with improvements in both EBITDA and net profit. Strategic initiatives, including the recent acquisition of the global brand Kenalog®, alongside continued capacity expansions, are expected to drive this anticipated recovery.
About Piramal Pharma
Piramal Pharma operates as a global, integrated pharmaceutical company with two primary divisions: Pharma Solutions, which offers contract development and manufacturing (CDMO) services for global drugmakers, and Consumer Healthcare, focused on over-the-counter products. Piramal Pharma was established as a separate entity after its demerger from Piramal Enterprises Ltd. in August 2022.
Strategic Acquisitions and Expansion
The company is actively expanding its Pharma Solutions business. It recently acquired the global brand Kenalog® (triamcinolone acetonide) for an upfront payment of US$35 million, with potential contingent payments up to US$65 million. This move is set to strengthen its Complex Hospital Generics (CHG) portfolio. Significant capital expenditures are underway, with US$94 million invested in FY26 and a planned US$90 million for FY27. These investments are targeting sterile injectable and payload-linker capacities at its Lexington and Riverview facilities.
Impact on Business Segments
The strategic acquisition of Kenalog® is expected to diversify and reinforce Piramal Pharma's Complex Hospital Generics segment. Investments in sterile injectable and payload-linker capacities are designed to boost future revenue streams for the Pharma Solutions division. Meanwhile, the Consumer Healthcare segment's Power Brands and e-commerce channels show strong growth potential.
Key Risks and Challenges
The company faces potential hurdles that could delay its anticipated recovery. Continued inventory destocking and a slow inflow of early-stage orders remain concerns. Supply constraints within the Injectable Pain Management portfolio require prompt resolution. The impairment charge on intangible assets also signals a reassessment of commercial viability, which could affect asset valuations. Performance in international markets for its inhalation anesthesia products is another key factor to monitor.
Industry Peers
Piramal Pharma's Pharma Solutions segment operates in a competitive landscape alongside other global CDMOs and Indian pharmaceutical firms. Key Indian competitors in contract manufacturing and API production include Divi's Laboratories, Laurus Labs, and Syngene International. For FY25, Laurus Labs reported revenue of ₹5,025 crore and EBITDA of ₹1,214 crore. Syngene International posted revenue of ₹3,055 crore and EBITDA of ₹750 crore. Divi's Laboratories, a prominent API manufacturer, reported FY25 revenue of ₹7,770 crore and EBITDA of ₹2,802 crore.
Financial Snapshot
Consolidated Net Debt stood at ₹4,140 crore as of March 31, 2026, a marginal decrease from ₹4,199 crore in the prior fiscal year. On a standalone basis, Piramal Consumer Healthcare's Power Brands saw 24% year-on-year growth in FY26, while its e-commerce sales increased by 48% during the same period.
What to Watch Next
Investors will be closely monitoring Piramal Pharma's FY27 financial performance for clear signs of a revenue, EBITDA, and PAT turnaround. Key areas of focus include the successful integration and ramp-up of the Kenalog® business, resolution of supply chain issues for its Injectable Pain Management products, and sustained growth in international markets for inhalation anesthesia. Progress on the significant capital expenditure for expanding sterile injectable and payload-linker capacities will also be crucial.